[1] Chen, YP.Renal damage associated with Chinese Herbal Medicine[J]. Journal of Clinical Internal Medicine,2003,20(4):174-175. [2] 梁爱华,高月,张伯礼. 含马兜铃酸中药的安全性问题及对策[J].中国食品药品监管,2017(11):17-20. [3] Jadot I, Dedeves AE, Nortier J, et al., An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature[J]. Int J Mol Sci, 2017,18(2):297. [4] Lemy A, Wissing KM, Nortier J, et al.Late on set of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy:a case series with 15-year follow-up[J].Am J Kidney Dis,2008,51(3):471-477. [5] Chan W, Luo H B, Zheng Y, et al.Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats[J].Drug Metab Dispos, 2007,35(6): 866-874. [6] Stiborova M, Frei E, Arlt V M, et al.Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy[J]. Mutat Res, 2008, 658(1-2): 55-67. [7] Schmeiser HH, Stiborova M, Arlt VM.Chemical and molecular basis of the carcinogenicity of Aristolochia plants[J]. Curr Opin Drug Discov Devel, 2009, 12(1):141-148. [8] Xiao Y, Ge M, Xue X, et al.Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity[J]. Kidney Int,2008, 73(11): 1231-1239. [9] Xue X, Xiao Y, Zhu H, et al.Induction of P450 1A by 3-methyl-cholanthrene protects mice from aristolochic acid-I-induced acute renal injury[J]. Nephrol Dial Transplant, 2008, 23(10):3074-3081. [10] Krumbiegel G, Hallensleben J, Mennicke WH, et al.Studies on the metabolism of aristolochic acids I and II[J]. Xenobiotica,1987, 17(8): 981-991. [11] Schmeiser HH, Pool BL, Wiessler M.Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver[J]. Carcino-genesis, 1986, 7(1): 59-63. [12] Williams JA, Hyland R, Jones BC, et al.Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure(AUCI/AUC)ratios[J]. Drug Metab Dispos, 2004, 32(11):1201-1208. [13] 艾国民, 王庆敏, 邹东云, 等. 高效液相色谱法测定家蝇细胞色素P450O-脱甲基活性[J]. 分析化学, 2009, 37(8):1157-1160. [14] Benz RJ, Granneman GR.Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions[J].Clin Pharmacokinet, 1997, 32(3):210-258. [15] Stiborova M, Frei E, Wiessler M, et al.Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids:evidence for reductive activation by cytochromes P450 1A1 and 1A2[J]. Chem Res Toxicol,2001, 14(8): 1128-1137. [16] Stiborova M, Frei E, Hodek P, et al.Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH: cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer[J]. Int J Cancer, 2005, 113(2): 189-197. [17] Shi Z, Chen Y, Dong H, et al.Generation of a 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-)_Ahr d mouse line harboring the poor-affinity aryl hydrocarbon receptor[J]. Biochem Biophys Res Commun,2008, 376(4):775-780. [18] De Loor H, Meijers BK, Meyer TW, et al.Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography[J]. Chromatogr A,2009,1216(22):4684-4688. [19] 崔媛,李海山,宋乃宁等. 马兜铃酸I影响小鼠肝脏脂肪酸β氧化和糖代谢以及TCA 循环的代谢组学研究[J]. 中国药物警戒,2019,16(8):449-466. [20] Deguchi T, Ohtsuki S, Otagiri M, et al.Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney[J].Kidney Int,2002,61(5):1760-1768. [21] Muniz Martinez MC, Nortier J, Vereerstraeten P, et al.Progression rate of chinese herb nephropathy: impact of aristolo-chiafangchi in gested dose[J]. Nephrol Dial Transplant,2002,17(3):408-412. [22] Cosyns JP.Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date[J]. Drug Safe.2003,26(1):33-48. [23] 中国人民解放军肾脏病专业协作组. 2001例血液透析患者病因分析及高血压和贫血治疗状况[J].中国血液净化,2005,4(5):235-238. [24] Pahl MV, Vaziri ND.The chronic kidney disease-colonic axis[J].Sermin Dial,2015,28(5):459-463. |